The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications

Anne-Sophie von Krogh; Johanna A. Kremer Hovinga; Geir E. Tjønnfjord; Ingrid M. Ringen; Bernhard Lämmle; Anders Waage; Petter Quist-Paulsen

doi:10.1160/TH13-08-0713

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2014; 111(06): 1180-1183
DOI: 10.1160/TH13-08-0713

Letters to the Editor

Schattauer GmbH

The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications

Anne-Sophie von Krogh

¹Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology and Department of Haematology, St Olavs Hospital Trondheim University Hospital, Trondheim, Norway

,

Johanna A. Kremer Hovinga

²Department of Haematology and Central Haematology Laboratory, Bern University Hospital and University of Bern, Inselspital, Bern, Switzerland

,

Geir E. Tjønnfjord

³Department of Haematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway

,

Ingrid M. Ringen

⁴Department of Obstetrics and Gynaecology, St Olavs Hospital Trondheim University Hospital, Trondheim, Norway

,

Bernhard Lämmle

²Department of Haematology and Central Haematology Laboratory, Bern University Hospital and University of Bern, Inselspital, Bern, Switzerland

⁵Center for Thrombosis and Hemostasis (CTH), University Medical Center, Mainz, Germany

,

Anders Waage

¹Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology and Department of Haematology, St Olavs Hospital Trondheim University Hospital, Trondheim, Norway

,

Petter Quist-Paulsen

¹Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology and Department of Haematology, St Olavs Hospital Trondheim University Hospital, Trondheim, Norway

› Author Affiliations

Abstract

Full Text

References

References
1 George JN. The association of pregnancy with thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Curr Opin Hematol 2003; 10: 339-344.
2 Vesely SK, Li X, McMinn JR. et al. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Transfusion 2004; 44: 1149-1158.
3 Moatti-Cohen M, Garrec C, Wolf M. et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012; 119: 5888-5897.
4 Kokame K, Nobe Y, Kokubo Y. et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
5 Kremer Hovinga JA, Mottini M, Lammle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 2006; 04: 1146-1148.
6 Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
7 Kokame K, Matsumoto M, Soejima K. et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002; 99: 11902-11907.
8 Fujimura Y, Matsumoto M, Kokame K. et al. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol 2009; 144: 742-754.
9 Deal T, Kremer Hovinga JA, Marques MB. et al. Novel ADAMTS13 mutations in an obstetric patient with Upshaw-Schulman syndrome. J Clin Apher 2013; 28: 311-316.
10 Stella CL, Dacus J, Guzman E. et al. The diagnostic dilemma of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the obstetric triage and emergency department: lessons from 4 tertiary hospitals. Am J Obstet Gynecol 2009; 200: 381 e1-6.
11 Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001; 14: 437-454.
12 Stirling Y, Woolf L, North WR. et al. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176-182.
13 Mannucci PM, Canciani MT, Forza I. et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-2735.
14 Camilleri RS, Cohen H, Mackie IJ. et al. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost 2008; 06: 331-338.
15 Camilleri RS, Scully M, Thomas M. et al. A phenotype-genotype correlation of ADAMTS13 mutations in congenital TTP patients treated in the United Kingdom. J Thromb Haemost 2012; 10: 1792-1801.
16 George JN, Al-Nouri ZL. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematology Am Soc Hematol Educ Program 2012; 2012: 604-609.
17 Bianchi V, Robles R, Alberio L. et al. Von Wille-brand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710-713.
18 Lattuada A, Rossi E, Calzarossa C. et al. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003; 88: 1029-1034.
19 Pourrat O, Coudroy R, Pierre F. ADAMTS13 deficiency in severe postpartum HELLP syndrome. Br J Haematol 2013; 163: 409-410.

Supplementary Material

Online Supplementary Material (PDF)